Brief: Satsuma Pharmaceuticals Announces Positive Results From The Ongoing STS101 Ascend Phase 3 Open-Label, Long-Term Safety Trial

Satsuma Pharmaceuticals

20/09/2022 14:23

Sept 20 (Reuters) - Satsuma Pharmaceuticals Inc  STSA.O :
    * SATSUMA PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM
THE
ONGOING STS101 ASCEND PHASE 3 OPEN-LABEL, LONG-TERM SAFETY TRIAL
    * SATSUMA PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM
THE
ONGOING STS101 ASCEND PHASE 3 OPEN-LABEL, LONG-TERM SAFETY TRIAL
    * SATSUMA PHARMACEUTICALS INC - STS101 DEMONSTRATED A
FAVORABLE
SAFETY AND TOLERABILITY PROFILE, CONSISTENT WITH CLINICAL
EXPERIENCE TO DATE
    * SATSUMA - SUBJECT EXPOSURES OVER TIME WITH STS101MK2
EXCEED FDA
REQUIREMENT TO SUPPORT PLANNED NDA SUBMISSION IN Q1 2023, AND
POTENTIAL APPROVAL
    * SATSUMA- SUBJECTS USING STS101MK2 TO TREAT MIGRAINE
ATTACKS
ACHIEVED FREEDOM FROM PAIN BY 2 HOURS POST-TREATMENT IN 34.2% OF
TREATED ATTACKS
    * SATSUMA- SUBJECTS USING STS101MK2 TO TREAT MIGRAINE
ATTACKS
ACHIEVED FREEDOM FROM MBS BY 2 HOURS POST-TREATMENT IN 53.4% OF
TREATED ATTACKS
    * SATSUMA - IN EXPLORATORY POST-HOC ANALYSES, STS101MK2
DEMONSTRATED IMPROVED CLINICAL PERFORMANCE VERSUS STS101MK1

Source text for Eikon:  ID:nGNX9RKh6R 
Further company coverage:  STSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))